Pharmaceutical product development technologies based on the biopharmaceutical classification system.
Poor solubility and poor permeability account for many pharmacokinetic failures and about thirty percent of drug molecules are rejected due to pharmacokinetic failures. When poor pharmaceutical properties are discovered in development, the cost of bringing a potent, but poorly absorbable molecule to the product stage by formulation can become very high. Fast and reliable in vitro prediction strategies are needed to filter out problematic molecules at the earliest stage of discovery. This communication will consider recent developments in physiochemical profiles used to identify molecules with physical properties related to good oral absorption. FDA's biopharmaceutical classification system (BCS) is an attempt to rationalize the critical components related to oral absorption and utilization of these principles for selection of a suitable technology to serve the interests of the early stages of drug discovery.
Jain
D
D
Rajiv Academy for Pharmacy, Mathura, Uttar Pradesh, India.
Pathak
D
D
Pathak
K
K
D000818:Animals; D001702:Biopharmaceutics / Q000145:classification*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007408:Intestinal Absorption; D036103:Nanotechnology; D004364:Pharmaceutical Preparations / Q000145:classification*; D010599:Pharmacokinetics; D013678:Technology, Pharmaceutical / Q000639:trends*
D004364:Pharmaceutical Preparations